Related references
Note: Only part of the references are listed.Association of Cardiovascular Risk Factors With Mental Health Diagnoses in Iraq and Afghanistan War Veterans Using VA Health Care
Beth E. Cohen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration
G. J. H. Dumont et al.
SOCIAL NEUROSCIENCE (2009)
Oxytocin shapes the neural circuitry of trust and trust adaptation in humans
Thomas Baumgartner et al.
NEURON (2008)
Plasma pharmacokinetics of 3.4-methylenedioxymethamphetamine after controlled oral administration to young adults
Erin A. Kolbrich et al.
THERAPEUTIC DRUG MONITORING (2008)
The relative efficacy of bona fide psychotherapies for treating post-traumatic stress disorder: A meta-analysis of direct comparisons
Steven G. Benish et al.
CLINICAL PSYCHOLOGY REVIEW (2008)
Pharmacological interaction between 3,4-methylenedioxymethamphetamine (Ecstasy) and paroxetine:: Pharmacological effects and pharmacokinetics
Magi Farre et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
A role for oxytocin and 5-HT1A receptors in the prosocial effects of 3,4-methylenedioxymethamphetamine (ecstasy)
M. R. Thompson et al.
NEUROSCIENCE (2007)
Oxytocin improves mind-reading in humans
Gregor Domes et al.
BIOLOGICAL PSYCHIATRY (2007)
The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans
Manuel Tancer et al.
PSYCHOPHARMACOLOGY (2007)
Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder
Barbara O. Rothbaum et al.
JOURNAL OF TRAUMATIC STRESS (2006)
Combining pharmacotherapy with cognitive behavioral therapy: Traditional and new approaches
Michael Davis et al.
JOURNAL OF TRAUMATIC STRESS (2006)
Neurocircuitry models of posttraumatic stress disorder and extinction: Human neuroimaging research - Past, present, and future
Scott L. Rauch et al.
BIOLOGICAL PSYCHIATRY (2006)
Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population
K Wolff et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2006)
Oxytocin modulates neural circuitry for social cognition and fear in humans
P Kirsch et al.
JOURNAL OF NEUROSCIENCE (2005)
Oxytocin is associated with human trustworthiness
PJ Zak et al.
HORMONES AND BEHAVIOR (2005)
Oxytocin increases trust in humans
M Kosfeld et al.
NATURE (2005)
Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication
RC Kessler et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
Ecstasy (MDMA) mimics the post-orgasmic state: Impairment of sexual drive and function during acute MDMA-effects may be due to increased prolactin secretion
T Passie et al.
MEDICAL HYPOTHESES (2005)
Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care
CW Hoge et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Burden of medical illness in women with depression and posttraumatic stress disorder
SM Frayne et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
What is a mood stabilizer? An evidence-based response
MS Bauer et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
Do patients drop out prematurely from exposure therapy for PTSD?
EA Hembree et al.
JOURNAL OF TRAUMATIC STRESS (2003)
Common mental disorders in postconflict settings
JTVM de Jong et al.
LANCET (2003)
Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans
DS Harris et al.
PSYCHOPHARMACOLOGY (2002)
The subjective effects of MDMA and mCPP in moderate MDMA users
ME Tancer et al.
DRUG AND ALCOHOL DEPENDENCE (2001)
Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study
RD Marshall et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
Gender differences in the subjective effects of MDMA
ME Liechti et al.
PSYCHOPHARMACOLOGY (2001)
Clinician-administered PTSD scale: A review of the first ten years of research
FW Weathers et al.
DEPRESSION AND ANXIETY (2001)
3,4-methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H215O]-PET in healthy humans
A Gamma et al.
NEUROPSYCHOPHARMACOLOGY (2000)
Human pharmacology of 3,4-methylenedioxymethamphetamine (ecstasy):: Psychomotor performance and subjective effects
J Camí et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2000)
Efficacy and safety of sertraline treatment of posttraumatic stress disorder - A randomized controlled trial
K Brady et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) are attenuated by the serotonin uptake inhibitor citalopram
ME Liechti et al.
NEUROPSYCHOPHARMACOLOGY (2000)
Traumatic events and post-traumatic stress disorder in the community: prevalence, risk factors and comorbidity
A Perkonigg et al.
ACTA PSYCHIATRICA SCANDINAVICA (2000)
The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers
ME Liechti et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2000)
Share Paper
